{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-006131","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.559031+00:00","generated_at":"2026-06-02T01:25:42.505211+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tenax Therapeutics Q1 net loss widens to $3.8M; Phase 3 LEVEL study enrolling","bullets":["Net loss of $3.8M vs $1.4M in Q1 2023; R&D expenses rose to $2.7M from $0.3M.","Cash $12.5M; raised ~$8.0M net in Feb 2024 public offering.","Phase 3 LEVEL study for PH-HFpEF enrolling; 24 sites initiated, 152 patients planned.","Secured global development/commercial rights to levosimendan in PH-HFpEF; new patent issued (US 11,969,424).","Topline data from LEVEL expected second half 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-006131","json":"https://secwatch.observer/filing/0001654954-24-006131.json","markdown":"https://secwatch.observer/filing/0001654954-24-006131.md","text":"https://secwatch.observer/filing/0001654954-24-006131.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495424006131/0001654954-24-006131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495424006131/tenx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:25:42.505211+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a3d4aeaaa013873f89a9e61d2e6ab9220f318ff","claim":"TENAX THERAPEUTICS, INC. reported first quarter ended March 31, 2024 results: net income $3.8 million.","evidence_excerpt":"Tenax Therapeutics reported a net loss for the first quarter of 2024 of $3.8 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424006131/0001654954-24-006131-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"$3.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}